Evidence map›Paper›PMID 21368772›Full record

Trial reportGenes and immunity2011

The role of HLA-DR-DQ haplotypes in variable antibody responses to anthrax vaccine adsorbed.

N M Pajewski, S D Parker, G A Poland, I G Ovsyannikova, W Song, K Zhang, B A McKinney, V S Pankratz, J C Edberg, R P Kimberly and 3 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in Genes and immunity, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00119067 (Anthrax Vaccine Adsorbed), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00119067 phase4completednot on this map

Anthrax Vaccine Adsorbed: Human Reactogenicity and Immunogenicity Trial to Address Change in Route of Administration and Dose Reduction

TypeinterventionalSponsorCenters for Disease Control and PreventionRan2002 to 2010Enrolled1,564ConditionsHealthyArmsAnthrax Vaccine Adsorbed, Saline injection
3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 39 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. The immunogenetics of COVID-19.Immunogenetics · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Correlation of HLA-DQB1 gene polymorphism of Xinjiang Uygur with outcome of HBV infection.International journal of clinical and experimental medicine · 2015
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

N M PajewskiSection on Statistical Genetics, University of Alabama at Birmingham, Birmingham, AL 35294-0022, USA.
S D Parker
G A Poland
I G Ovsyannikova
W Song
K Zhang
B A McKinney
V S Pankratz
J C Edberg
R P Kimberly
R M Jacobson
J Tang
R A Kaslow
University of Alabama at Birmingham · USMayo Clinic in Florida · USUniversity of Tulsa · US

Funding

UAB Statistical Genetics Post-Doctoral Training ProgramT32HL072757 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI TIWARI, HEMANT K. · 2003 to 2016
$3.8M
POPULATION GENETICS ANALYSIS PROGRAM IMMUNITY TO VACCINES/INFECTION-266040068N01AI040068 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KASLOW, RICHARD ALAN · 2006 to 2006
–
NHLBI NIH HHS T32 HL072757NIAID NIH HHS N01 AI040068
6 · The paper itself

Abstract

Host genetic variation, particularly within the human leukocyte antigen (HLA) loci, reportedly mediates heterogeneity in immune response to certain vaccines; however, no large study of genetic determinants of anthrax vaccine response has been described. We searched for associations between the immunoglobulin G antibody to protective antigen (AbPA) response to Anthrax Vaccine Adsorbed (AVA) in humans, and polymorphisms at HLA class I (HLA-A, -B, and -C) and class II (HLA-DRB1, -DQA1, -DQB1, -DPB1) loci. The study included 794 European-Americans and 200 African-Americans participating in a 43-month, double-blind and placebo-controlled clinical trial of AVA (clinicaltrials.gov identifier NCT00119067). Among European-Americans, genes from tightly linked HLA-DRB1, -DQA1, -DQB1 haplotypes displayed significant overall associations with longitudinal variation in AbPA levels at 4, 8, 26 and 30 weeks from baseline in response to vaccination with three or four doses of AVA (global P=6.53 × 10(-4)). In particular, carriage of the DRB1-DQA1-DQB1 haplotypes (*)1501-(*)0102-(*)0602 (P=1.17 × 10(-5)), (*)0101-(*)0101-(*)0501 (P=0.009) and (*)0102-(*)0101-(*)0501 (P=0.006) was associated with significantly lower AbPA levels. In carriers of two copies of these haplotypes, lower AbPA levels persisted following subsequent vaccinations. No significant associations were observed amongst African-Americans or for any HLA class I allele/haplotype. Further studies will be required to replicate these findings and to explore the role of host genetic variation outside of the HLA region.

Indexed as

AdultAgedAllelesAnthraxAnthrax VaccinesAntibody FormationFemaleGene FrequencyGenetic VariationGenotypeHaplotypesHistocompatibility Antigens Class IHLA-DQ AntigensHLA-DR AntigensHumansImmunoglobulin GAnthrax VaccinesHistocompatibility Antigens Class IHLA-DQ AntigensHLA-DR AntigensImmunoglobulin G

Identifiers

PMID21368772
PMCPMC3165112
OpenAlexW2014308000

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.